These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31075399)

  • 41. Pharmacological Modulation of BET Family in Sepsis.
    Wang N; Wu R; Comish PB; Kang R; Tang D
    Front Pharmacol; 2021; 12():642294. PubMed ID: 33776776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains.
    Wang Q; An X; Xu J; Wang Y; Liu L; Leung EL; Yao X
    Org Biomol Chem; 2018 Sep; 16(35):6521-6530. PubMed ID: 30160288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physachenolide C is a Potent, Selective BET Inhibitor.
    Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
    J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations.
    Tong JB; Xiao XC; Luo D; Xu HY; Xing YC; Gao P; Liu Y
    Mol Divers; 2024 Apr; 28(2):671-692. PubMed ID: 36773087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
    Gilan O; Rioja I; Knezevic K; Bell MJ; Yeung MM; Harker NR; Lam EYN; Chung CW; Bamborough P; Petretich M; Urh M; Atkinson SJ; Bassil AK; Roberts EJ; Vassiliadis D; Burr ML; Preston AGS; Wellaway C; Werner T; Gray JR; Michon AM; Gobbetti T; Kumar V; Soden PE; Haynes A; Vappiani J; Tough DF; Taylor S; Dawson SJ; Bantscheff M; Lindon M; Drewes G; Demont EH; Daniels DL; Grandi P; Prinjha RK; Dawson MA
    Science; 2020 Apr; 368(6489):387-394. PubMed ID: 32193360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression.
    Zhou Z; Li X; Liu Z; Huang L; Yao Y; Li L; Chen J; Zhang R; Zhou J; Wang L; Zhang QQ
    Front Pharmacol; 2020; 11():1043. PubMed ID: 32765266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclic adenosine monophosphate response-element binding protein activation by mitogen-activated protein kinase-activated protein kinase 3 and four-and-a-half LIM domains 5 plays a key role for vein graft intimal hyperplasia.
    Nakanishi K; Saito Y; Azuma N; Sasajima T
    J Vasc Surg; 2013 Jan; 57(1):182-93, 193.e1-10. PubMed ID: 23127979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation.
    McDonald RA; White KM; Wu J; Cooley BC; Robertson KE; Halliday CA; McClure JD; Francis S; Lu R; Kennedy S; George SJ; Wan S; van Rooij E; Baker AH
    Eur Heart J; 2013 Jun; 34(22):1636-43. PubMed ID: 23530023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts.
    Zou J; Zhang X; Yang H; Zhu Y; Ma H; Wang S
    Ann Vasc Surg; 2011 May; 25(4):538-46. PubMed ID: 21549923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recruitment of Brd3 and Brd4 to acetylated chromatin is essential for proinflammatory cytokine-induced matrix-degrading enzyme expression.
    Dai J; Zhou S; Ge Q; Qin J; Li J; Ju H; Cao Y; Zheng M; Li C; Gao X; Teng H; Jiang Q
    J Orthop Surg Res; 2019 Feb; 14(1):59. PubMed ID: 30786900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
    Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
    Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
    Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
    Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppressor of cytokine signaling 3 is a negative regulator for neointimal hyperplasia of vein graft stenosis.
    Xiang S; Liu J; Dong N; Shi J; Xiao Y; Wang Y; Hu X; Gong L; Wang W
    J Vasc Res; 2014; 51(2):132-43. PubMed ID: 24685947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1.
    Liao L; Alicea-Velázquez NL; Langbein L; Niu X; Cai W; Cho EA; Zhang M; Greer CB; Yan Q; Cosgrove MS; Yang H
    Mol Oncol; 2019 Apr; 13(4):811-828. PubMed ID: 30585695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.
    Kim JH; Pandit N; Yoo M; Park TH; Choi JU; Park CH; Jung KY; Lee BI
    Sci Rep; 2023 Jul; 13(1):10805. PubMed ID: 37402749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.
    Andrieu G; Tran AH; Strissel KJ; Denis GV
    Cancer Res; 2016 Nov; 76(22):6555-6567. PubMed ID: 27651315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
    Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
    ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.